---
title: 'ISPOR Webinar: FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2'
author: ''
date: '2023-03-07T06:00:00'
slug: fda-patient-focused-drug-development
categories: []
tags: []
type: webinar
url_freeregister: https://www.ispor.org/conferences-education/calendar/event/2023/03/07/default-calendar/fda-patient-focused-drug-development-(pfdd)-guidance---part-2
url_register: ~
url_slides: ~
url_video: no
url_agenda: ~
url_website: ~
url_audio: ~
url_code: ~
url_pdf: ~
date_end: '2023-03-07T07:00:00'
all_day: no
publishDate: '2023-03-09T11:15:33-08:00'
featured: no
image:
  caption: ''
  focal_point: ''
  preview_only: no
slides: ''
projects: []
location: ~
address:
  street: ~
  city: ~
  region: ~
  postcode: ~
  country: ~
summary: ~
abstract: ~
speaker: Eric Gascho (National Health Council) | Robyn Bent (FDA) | Michelle Tarver (FDA)
---

<!--more-->
- Inform the ISPOR membership about the FDA PFDD initiative in general, the four PFDD guidance documents more specifically, and the various ways PFDD might impact the work they do in HEOR, clinical outcome assessments (COA), regulatory science, and other areas.  
- Discuss draft guidance 3, for which a public comment period was recently conducted, and what is required in guidance 4.    
- Provide insights on how the guidance documents can be used.  
- Provide insights on the future of PFDD.